Skip to main content

13-11-2019 | Rheumatoid arthritis | Video | Article

Researcher comment: The NORD-STAR trial

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).  


Back to the ACR/ARP 2019 conference hub

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

JAK inhibitor safety

Data summary and expert discussion on the potential risks associated with JAK inhibitors.

Image Credits